Frontier Biotechnologies Receives American Patent For Anti-HIV Drug
This article was originally published in PharmAsia News
Executive Summary
Frontier Biotechnologies has received a patent for its new anti-HIV drug Albuvirtide in the U.S., paving the way to enter the global market. To date, the Chongqing firm has patented the drug in more than 10 countries. Since May 2008, Phase I clinical trials of Albuvirtide being conducted in Beijing show positive results for long-acting effects, safety and reduction of virus (PharmAsia News, Sept. 22, 2008). The trial is expected to complete by the third quarter of 2009, to be followed by Phase II and Phase III trials. Frontier Biotechnologies will apply to China's State FDA to market the new drug after completing clinical trials, likely next year. (Click here for more - Chinese Language)